清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study

伦瓦提尼 医学 索拉非尼 内科学 危险系数 肿瘤科 甲状腺癌 甲状腺癌 耐火材料(行星科学) 回顾性队列研究 实体瘤疗效评价标准 进行性疾病 甲状腺 置信区间 肝细胞癌 疾病 物理 天体生物学
作者
Mijin Kim,Meihua Jin,Min Ji Jeon,Eui Young Kim,Dong Yeob Shin,Dong‐Jun Lim,Bo Hyun Kim,Ho‐Cheol Kang,Won Bae Kim,Young Kee Shong,Hee Kyung Kim,Won Gu Kim
出处
期刊:Thyroid [Mary Ann Liebert, Inc.]
卷期号:33 (1): 91-99 被引量:32
标识
DOI:10.1089/thy.2022.0054
摘要

Background: Sorafenib and lenvatinib have been widely adopted to treat radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). However, limited data exist regarding a direct comparison of these tyrosine kinase inhibitors (TKIs). We aimed to evaluate the clinical efficacy and safety of two TKIs as first-line therapy in patients with distant metastatic or locally advanced, progressive, RAI-refractory DTC in real-world practice. Methods: In this multicenter, retrospective cohort study, we evaluated 136 patients with progressive distant metastatic or locally advanced, progressive, RAI-refractory DTC or poorly differentiated thyroid carcinoma (PDTC) who received first-line sorafenib or lenvatinib treatment. The primary outcome was progression-free survival (PFS). We also evaluated the objective response rate, disease-control rate, clinical benefit rate, and safety. Results: The median age of the patients was 68 years, and 35% (47/136) were male. Eighty and fifty-six patients were included in the sorafenib and lenvatinib groups, respectively. The median PFS was 13.3 months [95% confidence interval, CI, 9.9-18.1 months] in the sorafenib group and 35.3 months [CI, 18.2 months to upper limit not reported as the median was not reached] in the lenvatinib group (p = 0.001). A significantly prolonged PFS was observed in the lenvatinib group (compared with the sorafenib group) after adjusting for age, sex, pathology, disease-related symptom, lung-only metastasis, cumulative RAI dose, time from diagnosis, treatment duration, and longest diameter of the target lesion (hazard ratio = 0.34, CI, 0.19-0.60, p < 0.001). The partial response rate was 24% and 59% in the sorafenib and lenvatinib groups, respectively (p < 0.001). More common grade 3-4 adverse events were hypertension (16%, 9/56 vs. 1%, 1/80, p = 0.002) and proteinuria (32%, 18/56 vs. 0%, p < 0.001) in the lenvatinib group, and hand-foot skin reaction (24%, 19/80 vs. 4%, 2/56, p = 0.001) in the sorafenib group. Conclusion: In our study of Asian patients, first-line lenvatinib treatment of metastatic or locally advanced, progressive, RAI-refractory DTC or PDTC was associated with a longer PFS compared with sorafenib. However, severe hypertension and proteinuria were observed more frequently after lenvatinib treatment than after sorafenib treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CHEN完成签到 ,获得积分10
9秒前
呆呆的猕猴桃完成签到 ,获得积分10
10秒前
文2026完成签到,获得积分10
12秒前
淡然的冬瓜完成签到,获得积分10
20秒前
47秒前
yipmyonphu的应助被科研通管家采纳,获得30
48秒前
49秒前
小成完成签到 ,获得积分10
51秒前
嘟嘟嘟嘟完成签到 ,获得积分10
1分钟前
1分钟前
叮咚鸡发布了新的文献求助10
1分钟前
宇文雨文完成签到 ,获得积分10
1分钟前
拼搏的小凝完成签到,获得积分10
1分钟前
房天川完成签到 ,获得积分10
1分钟前
吃鲨鱼的小虾米完成签到,获得积分10
1分钟前
画龙点睛完成签到 ,获得积分10
1分钟前
四颗半小核桃完成签到 ,获得积分10
2分钟前
aspect完成签到 ,获得积分10
2分钟前
hj完成签到 ,获得积分10
2分钟前
赘婿的应助被amiee采纳,获得10
2分钟前
南风完成签到 ,获得积分10
2分钟前
粟禾完成签到 ,获得积分10
2分钟前
2分钟前
轻歌水越完成签到 ,获得积分10
2分钟前
2分钟前
诺亚方舟哇哈哈完成签到 ,获得积分0
2分钟前
2分钟前
超级无敌万能小金毛完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
amiee发布了新的文献求助10
2分钟前
yong完成签到 ,获得积分10
3分钟前
科研通AI6.3的应助被spinon采纳,获得20
3分钟前
3分钟前
今后的应助被叮咚鸡采纳,获得10
3分钟前
小幺完成签到 ,获得积分10
3分钟前
mochalv123完成签到,获得积分10
3分钟前
ttplldd完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190242
求助须知:如何正确求助?哪些是违规求助? 9577380
关于积分的说明 21852403
捐赠科研通 7788815
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560109
邀请新用户注册赠送积分活动 2482945